SEC Form 3 · accession 0000899243-18-020085
CONSTELLATION PHARMACEUTICALS INC · CNST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James E Audia
Director
Period of report
Jul 18, 2018
Accepted (ET)
Jul 18, 2018 · 5:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434418
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 69,034 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.08 | holding | — | — | — | — | Mar 6, 2022 | Common Stock | 11,626 | — | D |
| Stock Option (right to buy)F2 | $5.62 | holding | — | — | — | — | Nov 8, 2025 | Common Stock | 8,515 | — | D |
| Stock Option (right to buy)F3 | $5.62 | holding | — | — | — | — | Nov 8, 2025 | Common Stock | 16,089 | — | D |
| Stock Option (right to buy)F4 | $7.60 | holding | — | — | — | — | Feb 18, 2026 | Common Stock | 1,277 | — | D |
| Stock Option (right to buy)F5 | $5.51 | holding | — | — | — | — | Feb 16, 2027 | Common Stock | 2,384 | — | D |
| Stock Option (right to buy)F6 | $5.51 | holding | — | — | — | — | Sep 13, 2027 | Common Stock | 9,083 | — | D |
| Stock Option (right to buy)F7 | $7.60 | holding | — | — | — | — | Mar 7, 2028 | Common Stock | 9,083 | — | D |
Explanation of responses
- F1This option was granted on March 7, 2012 and is fully vested.
- F2This option was granted on November 9, 2015 and is fully vested.
- F3This option was granted on November 9, 2015 and is fully vested.
- F4This option was granted on February 19, 2016 and is fully vested.
- F5This option was granted on February 17, 2017 and is fully vested.
- F6This option was granted on September 14, 2017 and is scheduled to vest as to 25% of the shares underlying the option on September 14, 2018, with the remainder vesting in equal quarterly installments through September 14, 2021.
- F7This option was granted on March 8, 2018 and is scheduled to vest as to 33% of the shares underlying the option on March 8, 2019, with the remainder vesting in equal quarterly installments through March 8, 2021.
Remarks
Exhibit Index: 24.1 Power of Attorney